What is the recommended treatment approach for atopic neurodermatitis?

Atopic Neurodermatitis Treatment Approach

For adults with atopic dermatitis (neurodermatitis), start with optimized topical therapy (emollients plus topical corticosteroids or calcineurin inhibitors), and if disease remains moderate-to-severe or significantly impacts quality of life despite topical treatment, advance to systemic therapy with dupilumab, tralokinumab, or JAK inhibitors (upadacitinib, abrocitinib, baricitinib) as first-line systemic agents. 1

Treatment Algorithm by Disease Severity

Mild Disease

• Emollients (moisturizers) as foundational therapy for all patients 2
• Topical corticosteroids for active inflammation
• Topical calcineurin inhibitors (tacrolimus, pimecrolimus), particularly for sensitive areas like face and intertriginous zones 2
• Newer topical agents: PDE-4 inhibitors (crisaborole, roflumilast) or topical JAK inhibitors (ruxolitinib) for steroid-sparing approaches 3, 2

Moderate-to-Severe Disease Refractory to Topicals

First-line systemic options (STRONG recommendations):

1. Biologics 1:

   • Dupilumab (IL-4/IL-13 inhibitor) - moderate certainty evidence
   • Tralokinumab (IL-13 inhibitor) - moderate certainty evidence
   • Lebrikizumab (IL-13 inhibitor) - newly approved 3
   • Nemolizumab (IL-31 receptor inhibitor) with concomitant topical therapy 3

2. JAK Inhibitors 1:

   • Upadacitinib (JAK1 inhibitor)
   • Abrocitinib (JAK1 inhibitor)
   • Baricitinib (JAK1/JAK2 inhibitor)

Second-line systemic options (CONDITIONAL recommendations):

1. Traditional immunosuppressants 1:

   • Cyclosporine (3-5 mg/kg/day) - limited to 1 year due to toxicity concerns; requires monitoring for renal function and hypertension 1
   • Methotrexate
   • Azathioprine
   • Mycophenolate mofetil/mycophenolic acid

2. Phototherapy (narrowband UVB preferred) - conditional recommendation with low certainty evidence 1

   • Requires 2-3 treatments weekly for 10-14 weeks
   • Main limitation is accessibility and time commitment
   • Long-term skin cancer risk, especially with PUVA

AVOID:

• Systemic corticosteroids - conditional recommendation AGAINST use due to rebound flares and adverse effects 1

Key Clinical Decision Points

When to Escalate to Systemic Therapy 4

Before advancing to systemic treatment, ensure you have:

• Optimized topical therapy with appropriate potency corticosteroids and adequate emollient use
• Ruled out alternative diagnoses: allergic contact dermatitis, cutaneous T-cell lymphoma, immunodeficiency
• Addressed trigger factors: irritants, allergens, stress
• Treated secondary infections (Staphylococcus aureus colonization/infection)
• Assessed quality of life impact: work/school performance, sleep disturbance, psychological burden
• Considered phototherapy if accessible and appropriate

Choosing Between Systemic Options

Prefer biologics or JAK inhibitors over traditional immunosuppressants because:

• Higher quality evidence (moderate certainty vs. low certainty) 1
• Superior efficacy profiles
• More favorable safety profiles
• No routine laboratory monitoring required for dupilumab/tralokinumab 1
• Targeted mechanism of action

Among biologics:

• Dupilumab and tralokinumab have the most robust evidence 1
• Conjunctivitis is common with dupilumab/tralokinumab but usually self-limited; manage with artificial tears, refer to ophthalmology if severe or persistent 1

Among JAK inhibitors:

• All three (upadacitinib, abrocitinib, baricitinib) have strong recommendations 1
• Consider FDA boxed warnings: increased risk of serious infections, malignancy, major cardiovascular events, and thrombosis
• Requires shared decision-making regarding risk-benefit profile

Traditional immunosuppressants:

• Reserve for cases where biologics/JAK inhibitors are not accessible, not tolerated, or have failed
• Cyclosporine limited to 1 year maximum due to nephrotoxicity and hypertension risk 1
• All require regular laboratory monitoring

Common Pitfalls to Avoid

1. Using systemic corticosteroids for chronic management - causes rebound flares upon discontinuation 1

2. Inadequate topical therapy trial - most patients need concomitant topical anti-inflammatory therapy even when on systemic agents 1

3. Missing alternative diagnoses - consider patch testing for allergic contact dermatitis, especially if refractory to standard treatment 1

4. Ignoring quality of life assessment - severity scores alone don't capture treatment need; psychological impact, sleep disturbance, and functional impairment are critical 4

5. Overlooking infection - Staphylococcus aureus colonization/infection can drive disease exacerbations and should be treated 4

Maintenance Therapy Considerations

• Proactive therapy: Consider maintenance with topical calcineurin inhibitors or lower-potency corticosteroids on previously affected areas 2-3 times weekly to prevent flares 5
• Concomitant topical therapy: Continue emollients and topical anti-inflammatory agents even when using systemic therapy 1
• Tapering biologics: After achieving control with dupilumab, dose reduction to 300 mg every 4 weeks may be considered after 16 weeks 1